MicroRNA-146b overexpression associates with deteriorated clinical characteristics, increased International Staging System stage, cacoethic chromosome abnormality, and unfavorable prognosis in multiple myeloma patients.

Abstract

BackgroundMicroRNA‐146b (miR‐146b) is a critical regulator and prognosis biomarker in several hematological malignancies, whereas its role in multiple myeloma (MM) was unclear. Therefore, this study aimed to investigate the significance of miR‐146b in MM patients.MethodsThe plasma cells were separated from bone marrow samples of 180 symptomatic MM patients (before treatment) and 50 healthy controls (HCs), and subsequently detected by reverse transcription‐quantitative polymerase chain reaction for miR‐146b expression.ResultsMiR‐146b was increased in MM patients compared with HCs (P < .001), and it predicted increased MM risk (area under curve (AUC): 0.879, 95% confidence interval (CI): 0.822‐0.936). For clinical parameters, miR‐146b was positively correlated with serum creatinine (P = .047), beta‐2‐microglobulin (P < .001), lactate dehydrogenase (P < .001), bone lesion (P = .027), International Staging System (ISS) stage (P < .001), and t (4; 14; P = .006), while negatively correlated with albumin (P = .004) in MM patients. For prognosis, miR‐146b was decreased in complete response (CR) patients compared with non‐CR patients (P = .025), as well as in overall response rate (ORR) patients compared with non‐ORR patients (P = .036), and it discriminated CR patients from non‐CR patients (AUC: 0.610, 95% CI: 0.523‐0.698) and distinguished ORR patients from non‐ORR patients (AUC: 0.602, 95% CI: 0.501‐0.703) in MM patients. Moreover, miR‐146b was correlated with worse progression‐free survival (P = .007) and overall survival (P = .014) in MM patients.ConclusionMiR‐146b was overexpressed in MM patients and predicted increased MM risk; meanwhile, it correlated with deteriorated clinical properties, increased ISS stage, cacoethic chromosome abnormality, and worse prognosis in MM patients.